After 40 Years, Is Vaccine For Group B Strep On Horizon?
Executive Summary
US FDA advisory committee debates possible endpoints to demonstrate vaccine effectiveness in maternal immunization; Pfizer, which has candidate in Phase I/II study, says use of surrogate endpoint of protection may be most feasible.
You may also be interested in...
Finance Watch: Three Neurology-Focused Firms Raise VC Mega-Rounds
Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns.
Finance Watch: Bitcoin For Biopharma? Agenus Gives BEST A Shot
Investors in a February Biotech Electronic Security Token (BEST) offering will be able to put their money behind a single Agenus asset – the PD-1 inhibitor AGEN2034. Also, financial and strategic updates from Gossamer, Aduro, Novo's REPAIR Impact Fund and more.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.